Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2025-16 - Empagliflozin

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2027 · 307 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-16 - Empagliflozin

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value is disclosed, making it impossible to assess potential revenue.

Contract ends automatically upon patent expiry or loss of market exclusivity, which could shorten the contract term.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of rebate contracts for Empagliflozin as per § 130c SGB V.
  • Standardized contract terms; no individual negotiations.
Afficher le résumé complet

Open House procedure for concluding rebate contracts (Rabattverträge) according to § 130c SGB V for the active ingredient Empagliflozin. The procedure is open to all eligible pharmaceutical entrepreneurs, with standardized contract terms and no exclusivity. The contract runs from July 1, 2025, to June 30, 2027. Participation is possible at any time during this period. No estimated contract value is provided.

Risques

No estimated contract value is disclosed, making it impossible to assess potential revenue.

Contract ends automatically upon patent expiry or loss of market exclusivity, which could shorten the contract term.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4(18) AMG.
  • Valid marketing authorization for the offered medicinal product.

Eligibility

  • Self-declaration of eligibility and reliability required.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-16 - Empagliflozin

Rebate contracts for the active ingredient Empagliflozin. The contract is open to all pharmaceutical entrepreneurs who meet the eligibility criteria. No individual negotiations; standardized conditions apply.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 29, 2027

Détails de la procédure

Date de publication
22 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
334433-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3